- Home
- BJRI vs GHRS Comparison
BJRI vs GHRS Comparison
Compare BJRI & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BJRI
- GHRS
- Stock Information
- Founded
- BJRI 1978
- GHRS 2018
- Country
- BJRI United States
- GHRS Ireland
- Employees
- BJRI N/A
- GHRS N/A
- Industry
- BJRI Restaurants
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- BJRI Consumer Discretionary
- GHRS Health Care
- Exchange
- BJRI Nasdaq
- GHRS Nasdaq
- Market Cap
- BJRI 978.8M
- GHRS 849.8M
- IPO Year
- BJRI 1996
- GHRS 2021
- Fundamental
- Price
- BJRI $45.99
- GHRS $12.31
- Analyst Decision
- BJRI Hold
- GHRS Strong Buy
- Analyst Count
- BJRI 5
- GHRS 8
- Target Price
- BJRI $38.25
- GHRS $30.63
- AVG Volume (30 Days)
- BJRI 440.0K
- GHRS 187.6K
- Earning Date
- BJRI 07-24-2025
- GHRS 05-08-2025
- Dividend Yield
- BJRI N/A
- GHRS N/A
- EPS Growth
- BJRI N/A
- GHRS N/A
- EPS
- BJRI 0.95
- GHRS N/A
- Revenue
- BJRI $1,367,941,000.00
- GHRS N/A
- Revenue This Year
- BJRI $5.50
- GHRS N/A
- Revenue Next Year
- BJRI $3.00
- GHRS N/A
- P/E Ratio
- BJRI $47.95
- GHRS N/A
- Revenue Growth
- BJRI 2.91
- GHRS N/A
- 52 Week Low
- BJRI $27.61
- GHRS $6.00
- 52 Week High
- BJRI $46.26
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- BJRI 66.34
- GHRS 52.37
- Support Level
- BJRI $43.00
- GHRS $12.43
- Resistance Level
- BJRI $46.17
- GHRS $13.15
- Average True Range (ATR)
- BJRI 1.30
- GHRS 0.99
- MACD
- BJRI -0.14
- GHRS -0.14
- Stochastic Oscillator
- BJRI 93.16
- GHRS 41.03
About BJRI BJ's Restaurants Inc.
BJ's Restaurants Inc is involved in the business of owning and operating restaurants. The company operates in a single operating segment that is full-service company-owned restaurants. It has geographic presence only in the United States of America.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.